Nobilis IB Primo QX


avian infectious bronchitis vaccine (live)

This medicine is authorised for use in the European Union.


This is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 19/09/2019

Authorisation details

Product details
Nobilis IB Primo QX
Agency product number
Active substance
live avian infectious bronchitis virus, strain D388
International non-proprietary name (INN) or common name
avian infectious bronchitis vaccine (live)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Intervet International B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

30/07/2019 Nobilis IB Primo QX - EMEA/V/C/002802 - IB/0007


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Live viral vaccines
  • Domestic fowl

Therapeutic indication

For active immunisation of chickens in order to reduce respiratory signs of avian infectious bronchitis caused by QX-like variants of infectious bronchitis virus.

Assessment history

How useful was this page?

Add your rating